SEC Form 4 · accession 0000899243-17-021279
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samarth Kulkarni
Officer — Chief Business Officer
Period of report
Aug 28, 2017
Accepted (ET)
Aug 30, 2017 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Aug 28, 2017 | S | 23,154 | $20.0899 | D | 110,893 | D | |
| Common Shares | Aug 30, 2017 | S | 4,000 | $20.00 | D | 106,893 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transaction at prices ranging from $20.00 to $20.25, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff at the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price.